molecular-imaging-discovery czt-gehc discovery 670 czt product web page overview image.jpg

Discovery NM/CT 670 CZT

Molecular imaging enables the search for a different kind of discovery. The kind that has the ability to have a lasting impact on the world. A true discovery. Not only is it proof of a new way to understand something hidden deep within us, it has the ability to transcend the individual to make a greater impact on all patients.

The search for true discovery is unique. It requires the right balance of technology and people. The technology to enable the search and the people to embrace it. People open to opportunity, who persistently look for a better way to do something. To continuously improve the world around them. The kind of person that embodies the spirit of discovery.

We collaborate every day with the great minds working in molecular imaging. It is through these partnerships that we recognize your ambition. We see your attempts to diagnose and stage disease earlier to improve patient outcomes. We know firsthand of your desire to conduct exciting research such as simultaneous dual-isotope studies so you can expand the reach of nuclear medicine's impact. And we realize you are continually trying to provide the most comfortable experience possible for your patients.

We share in your drive to make things better. It's why, for the past 60 years, we have stayed committed to developing the potential of nuclear medicine. And, it's what led us to the breakthrough CZT technology. Not every technological innovation has the ability to transform how we see and understand the world around us. CZT does. Its revolutionary detection capability is not only transforming our understanding of disease at the cellular level, it's even being used to record events at the astronomical level.

Introducing DiscoveryTM NM/CT 670 CZT, the first commercially-available general purpose SPECT/CT system powered by CZT technology. Help bring your theories to life with a system designed to leverage all that CZT can do. Engineered for improvements in lesion detection1, image quality and patient comfort and combined with advanced quantitative applications provided through XelerisTM, this system renews the promise of nuclear medicine's potential for true discovery.

Molecular imaging enables the search for a different kind of discovery. The kind that has the ability to have a lasting impact on the world. A true discovery. Not only is it proof of a new way to understand something hidden deep within us, it has the ability to transcend the individual to make a greater impact on all patients.

CZT is the key component to the future of nuclear medicine. Not only is it lighter and more compact than the Nal crystals used in analog technology, it is pixelated. Housed within smaller and sleeker 39 cm x 51 cm FOV Planar and SPECT detector heads, each individual detector is like the eye of a fly, with thousands of tiny 2.46 mm sized detectors working together to capture more events, more accurately. It also enables direct conversion. With CZT, each photon is directly converted into an electrical signal that accurately identifies its location and energy. This eliminates the signal loss and noise inherent in conventional SPECT/CT detection technology, recovering lost spatial and energy resolution.

Discovery NM/CT 670 CZT is the first general purpose system designed with this breakthrough detection technology. Combined with registered collimation to deliver higher resolution images, edge-to-edge performance allowing for more comfortable positioning of your patients and the latest in advanced quantitative applications provided by Xeleris, this system is capable of transforming the entire nuclear medicine experience.


product-product-categories-molecular-imaging-discovery czt-system images-Image-56.jpeg

Up to 75 percent reduction in injected dose or scan time2

product-product-categories-molecular-imaging-discovery czt-system images-Image-55.jpeg

Less than 4 minutes each for Bone SPECT and WB Bone exams3

product-product-categories-molecular-imaging-discovery czt-system images-image14.jpeg

Improved system spatial resolution, from 4.3 to 2.8 mm

product-product-categories-molecular-imaging-discovery czt-system images-image32.jpeg

Exceptional energy resolution, 6.3 percent compared to 9.5 percent

product-product-categories-molecular-imaging-discovery czt-system images-image34.jpeg

Greater than 40 percent improvement in SPECT contrast-to-noise ratio, an important factor in lesion detectability4

product-product-categories-molecular-imaging-discovery czt-system images-image35.jpeg

67 percent reduction in detector frame size, from 7.5 cm to 2.5 cm

product-product-categories-molecular-imaging-discovery czt-system images-image36.jpeg

Optimal FOV 25 percent greater than Nal, maintaining image quality towards smaller edges

product-product-categories-molecular-imaging-discovery czt-system images-image37.jpeg

1.4 times higher count rates than conventional technology

product-product-categories-molecular-imaging-discovery czt-system images-image38.jpeg

Easy upgrade path from Discovery 670 DR to deliver CZT technology

product-product-categories-molecular-imaging-discovery czt-system images-image39.jpeg

Low CT dose with ASiRTM,5 technology and Q.AC

As molecular imaging continues to move toward the development of disease specific diagnoses and increasingly personalized care, clinicians are looking for technology that will get them there. For nuclear medicine, resolution is important. Early disease detection is only possible with a high system resolution that enables visualization of finer anatomic detail. In addition, research with multi-isotope exams requires precise energy resolution to reduce spillover between tracers.

With direct conversion detection, Discovery NM/CT 670 CZT has substantially improved system resolution by eliminating the signal loss and noise that comes with analog detection technology. It also uses a registered collimation design that aligns each collimator with a single detector pixel. This design eliminates the impact of collimator resolution that would normally effect the overall system resolution. The result is an improved contrast-to-noise ratio and spatial resolution down to 2.8 mm.

CZT can also simultaneously detect the energy from multiple tracers with more definition than conventional technology. Its 6.3 percent energy resolution makes it possible to explore new protocols with the variety of SPECT tracers available.


product-product-categories-molecular-imaging-discovery czt-system images-image6.jpeg

Continue your efforts to diagnose and stage disease earlier with smaller lesion detectability1

product-product-categories-molecular-imaging-discovery czt-system images-tubesimage.jpeg

Discover new protocols enabling differential diagnosis by visualizing multiple tracers simultaneously

product-product-categories-molecular-imaging-discovery czt-system images-image11.jpeg

More accurately assess treatment response to guide your treatment planning decisions with increased quantitation accuracy6

product-product-categories-molecular-imaging-discovery czt-system images-image30.jpeg

Enhance the patient experience by completing multiple exams in a single visit and single instances on the scanner bed

product-product-categories-molecular-imaging-discovery czt-system images-image14.jpeg

Increase patient satisfaction by reducing compromised exams, limiting repeat scans

product-product-categories-molecular-imaging-discovery czt-system images-image1.jpeg

Push nuclear medicine's boundaries by developing new diagnostic services

product-product-categories-molecular-imaging-discovery czt-system images-image10.jpeg

Grow patient volumes with referring physicians that value accurate, reproducible results and the diagnostic confidence you deliver


Pursue opportunities for tracer development and better utilization of currently available tracers

Often times, the technology needed to produce a specific result has an impact on the overall experience of getting that result. Many consumer industries have had to work around the design constraints that come with analog technology. For nuclear medicine, the crystal and photomultiplier tubes have to overlap beyond the useful field of view in order to limit image degradation at the edges. This creates a significant amount of unusable dead space at the edge of the detector making some procedures difficult, at times impossible, for patients to physically endure.

With a patient-centric design, certain exams become tolerable. One such exam is a cardiac SPECT scan requiring patients to extend and hold their arms above their head for a long duration. Also, more exams become available, such as whole-body procedures for taller patients and gurney scans for larger patients.

Just like the transition from analog to digital technology in other industries, the technology required to create a digital image is lighter, and more compact, with looser constraints on system design. Using registered collimation, Discovery NM/CT 670 CZT contains detected events entirely within a single pixel aligned to one collimator hole, even at the outermost edges of the FOV. This reduction in dead space enables a system design that can get closer to anatomies and increase patient comfort.


product-product-categories-molecular-imaging-discovery czt-system images-image14.jpeg

Improve imaging results by scanning in closer proximity to your patients

product-product-categories-molecular-imaging-discovery czt-system images-patientimage.jpeg

Provide more tolerable exams for greater patient comfort

product-product-categories-molecular-imaging-discovery czt-system images-image15.jpeg

Expand offerings that could provide economic and clinical benefits

The applications you use to interpret and communicate molecular information are just as important as the tracers used to highlight that information and the technology used to capture it.

Quantitative applications allow you to prove what you see and, more importantly, prove what can't be seen. They give you the assurance to determine the best course of treatment and the confidence to adapt treatment. They also give you the information to build a database of accurate results. Results that can be used to better inform the decisions you make for each patient and also, to inform the research that will develop more specific indications for disease.

Xeleris is our proven workstation dedicated to nuclear medicine. In the past, Xeleris led the way with mobilized applications that gave you accessible, easy-to-use tools to enhance productivity. Now, our latest version of Xeleris is leading the way with modern, quantitative applications for nuclear medicine; applications that help give you greater confidence of absolute quantitation in customizable, easy-to-read reports across multiple care areas.


product-product-categories-nuclear-medicine-xeleris-xeleris 4-qbrain-image1.jpg

Accurately diagnose neurodegenerative diseases with Q.Brain

product-product-categories-molecular-imaging-discovery czt-system images-image23.jpg

Diagnose pulmonary embolism by identifying V/Q mismatch with Q.Lung

product-product-categories-molecular-imaging-discovery czt-system images-image24.jpeg

Confidently classify patients eligible for lung resection surgeries with Q.Lung

product-product-categories-molecular-imaging-discovery czt-system images-image25.jpeg

Quantitate tracer uptake across any lesion or organ with Q.Metrix

product-product-categories-molecular-imaging-discovery czt-system images-image14.jpeg

Improve neurologic SPECT workflow with fast, reproducible and accurate quantitation of I-123 Ioflupane with DaTQUANTTM

product-product-categories-molecular-imaging-discovery czt-system images-image28.jpeg

Plan radioisotope therapy by measuring changes in tracer absorption over time with Dosimetry Toolkit

It takes a thoughtful mind to go in search of true discovery — a mind like yours that looks to establish new standards of care to have a lasting impact on the world around them. We appreciate your efforts to influence the future of medicine to benefits us all.

To help, we have worked with many of you to understand what obstacles stand in your way and what situations you seek. The result of our partnerships is Discovery NM/CT 670 CZT. We hope you see it as we do, as much more than another imaging product. We see it as a tool to help you to bring your theories to life.

1In clinical practice, the use of Discovery NM/CT 670 CZT may improve lesion detectability depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose or scan time to obtain diagnostic image quality for the particular clinical task.

2Together with Clarity 2D and Evolution7 and compared to Discovery NM/CT 670 Pro/ES/DR without Clarity 2D and Evolution7. As demonstrated in phantom testing using NEMA IEC Body Phantom.

3Together with Clarity 2D & Evolution7. Compared to typical 15 minute scan on Discovery NM/CT 670 Pro/ES/DR without Clarity 2D & Evolution7.

4Demonstrated in phantom testing using NEMA IEC Body Phantom at 50% scan times with Evolution7. Compared to Discovery NM/CT 670 Pro/ES/DR.

5In clinical practice, the use of ASiR may reduce CT patient dose depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task.

6In clinical practice, the use of Discovery NM/CT 670 CZT may improve quantitation of lesions larger than 5.5mL, depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose or scan time to obtain the claimed quantitation accuracy for the particular clinical task.

7In clinical practice, Evolution options7a (Evolution for Bone, Evolution for Cardiac, Evolution for Bone Planar) and Evolution Toolkit7b are recommended for use following consultation of a Nuclear Medicine physician, physicist and/or application specialist to determine the appropriate dose or scan time reduction to obtain diagnostic image quality for a particular clinical task, depending on the protocol adopted by the clinical site.

7aEvolution Options – Evolution claims are supported by simulation of count statistics using default factory protocols and imaging of 99mTc based radiotracers with LEHR collimator on anthropomorphic phantom or realistic NCAT – SIMSET phantom followed by quantitative and qualitative images comparison.

7bEvolution Toolkit – Evolution Toolkit claims are supported by simulation of full count statistics using lesion simulation phantom images based on various radiotracers and collimators and by showing that SPECT image quality reconstructed with Evolution Toolkit provide equivalent clinical information but have better signal-to-noise, contrast, and lesion resolution compare to the images reconstructed with FBP/OSEM.

Clarity Magazine


Clarity is back. We intend to publish Clarity semi-annually to offer you the latest information on both Molecular Imaging and CT innovations at GE Healthcare, all designed to help you achieve the best possible outcomes.

Click here to sign up for your complimentary subscription so you don’t miss a single edition of Clarity.